SCHEMBL915731

SCHEMBL915731

CC(OC(=O)NCC1CCC(C(=O)O)CC1)OC(=O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 3/20 0.37
PLG P00747 1/20 0.37
PLAT P00750 1/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP2C9 P11712 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 2/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL915872 1.00 KMT2A (0.50) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL915874 1.00 KMT2A (0.50) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL915987 1.00 KMT2A (0.50) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL915989 1.00 KMT2A (0.50) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL915151 1.00 KMT2A (0.50) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL915024 0.99 KMT2A (0.49) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL915020 0.99 KMT2A (0.49) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL914977 0.88 KMT2A (0.49) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL4696406 0.88 KMT2A (0.49) KMT2ASMN1; SMN2POLBPLGPLAT
SCHEMBL914978 0.88 KMT2A (0.49) KMT2ASMN1; SMN2POLBPLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372881-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2013-02-12 US claimed
US-20110184060-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG XENOPORT, INC. 2011-07-28 US claimed
WO-2011091164-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG XENOPORT, INC. (US) 2011-07-28 WO claimed
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2011-01-13 US claimed
EP-1919859-B1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE XENOPORT INC (US) 2010-06-02 EP claimed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US claimed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US claimed
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 EP disclosed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 US disclosed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 WO disclosed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 US disclosed
US-8372881-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2013-02-12 US disclosed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 US disclosed
WO-2010017504-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-02-11 WO disclosed
WO-2010017498-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-02-11 WO disclosed
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use XENOPORT, INC. (US) 2010-02-11 US disclosed
US-7592369-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2009-09-22 US disclosed
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-06-26 US disclosed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US disclosed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA KMT2A 741/4885SMN1; SMN2 2290/4885POLB 2686/4885
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use ACMSD, APEH, CPS1 KMT2A 1530/4885SMN1; SMN2 3931/4885POLB 3667/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA KMT2A 741/4885SMN1; SMN2 2290/4885POLB 2686/4885
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 KMT2A 1530/4885SMN1; SMN2 3931/4885POLB 3667/4885
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 KMT2A 1530/4885SMN1; SMN2 3931/4885POLB 3667/4885
US-20110184060-A1 ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG F2, PROC, PLAT KMT2A 1575/4885SMN1; SMN2 2850/4885POLB 3469/4885
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use ACMSD, APEH, CPS1 KMT2A 1530/4885SMN1; SMN2 3931/4885POLB 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.